Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Used in the treatment and prophylaxis of influenza A and B.
Administered via inhalation or intravenously in two daily doses.
The low plasma concentrations reached make it unlikely that significant amounts will transfer into breastmilk (Tanaka 2009).
Its very low oral absorption, 2% (Cass 1999), prevents transfer into infant plasma from breastmilk (Skalli 2010, Tanaka 2009).
Its use is authorized in infants from 6 months of age.
Various medical associations and expert consensus consider its use to be safe during breastfeeding (Skalli 2010, Chen 2010, Tanaka 2009, ABM 2009, AEM 2009).
See below the information of this related product: